健帆生物(300529) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 reached ¥378,881,893.33, an increase of 28.36% compared to ¥295,169,662.91 in the same period last year[3] - Net profit attributable to shareholders was ¥184,425,240.75, reflecting a growth of 42.32% from ¥129,584,330.84 year-on-year[3] - Net profit excluding non-recurring items was ¥188,722,755.82, up 55.35% from ¥121,479,332.62 in the previous year[3] - Operating profit for Q1 2020 was CNY 227.39 million, a 47.26% increase compared to Q1 2019, driven by higher sales[9] - Net profit for Q1 2020 reached CNY 183.85 million, reflecting a 42.11% increase from CNY 129.37 million in Q1 2019, primarily due to increased sales[9] - The total profit for Q1 2020 was CNY 216.14 million, a 41.76% increase compared to the previous year[9] - The company reported a total comprehensive income of ¥186.08 million for Q1 2020, compared to ¥131.47 million in Q1 2019, representing a growth of 41.5%[29] Cash Flow - Net cash flow from operating activities was ¥149,559,054.79, representing a 61.40% increase compared to ¥92,662,374.81 in the same period last year[3] - The company's cash flow from operating activities increased by 61.40% to CNY 149.56 million, attributed to higher sales collections[10] - Cash flow from operating activities in Q1 2020 was approximately ¥371.31 million, compared to ¥342.27 million in Q1 2019, showing an increase of 8.5%[30] - The total cash inflow from operating activities was CNY 410,225,101.13, an increase of 17.8% compared to CNY 348,195,434.89 in Q1 2019[33] - The company reported a net increase in cash and cash equivalents of -CNY 190,836,233.88 for Q1 2020, contrasting with an increase of CNY 57,244,095.51 in Q1 2019[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,714,021,000.21, an increase of 8.79% from ¥2,494,662,121.83 at the end of the previous year[3] - The total assets as of March 31, 2020, were CNY 2.71 billion, an increase from CNY 2.49 billion at the end of 2019[19] - The total liabilities amounted to CNY 353.27 million, compared to CNY 324.13 million in the previous year[18] - The company's total liabilities reached ¥368,667,448.41, up from ¥308,536,275.11, representing a 19.5% increase[22] - Total liabilities amounted to CNY 324,127,383.83, with current liabilities at CNY 262,633,102.43 and non-current liabilities at CNY 61,494,281.40[37] Shareholder Information - Basic earnings per share increased to ¥0.44, a rise of 41.94% from ¥0.31 in the previous year[3] - The total number of ordinary shareholders at the end of the reporting period was 10,940[6] - The largest shareholder, Dong Fan, holds 46.56% of the shares, totaling 194,949,611 shares[6] - Net assets attributable to shareholders reached ¥2,333,266,906.83, up 8.91% from ¥2,142,470,110.80 at the end of the previous year[3] Expenses and Costs - Total operating costs amounted to ¥155,419,695.08, slightly up from ¥151,495,279.47, with operating costs specifically rising from ¥43,327,109.08 to ¥54,042,634.13, reflecting a 24.8% increase[24] - Research and development expenses for the quarter were ¥12,175,518.59, a decrease of 8.7% from ¥13,331,913.16 in the previous year[24] - The company incurred research and development expenses of ¥10.21 million in Q1 2020, slightly down from ¥11.31 million in the previous year, indicating a decrease of 9.8%[27] Investment and Financial Assets - As of March 31, 2020, the company's financial assets measured at fair value amounted to CNY 300 million, primarily due to the purchase of financial products[9] - Investment income decreased by 68.13% to CNY 2.84 million, primarily due to a reduction in financial product purchases[10] - The company reported a net investment income of ¥2,841,669.95, down from ¥8,915,519.97, indicating a decline of 68.1%[24] Accounting and Reporting - The first quarter report was not audited, which may affect the reliability of the financial data presented[42] - The company has implemented new revenue and leasing standards, impacting the recognition of contract liabilities[40] - The company adjusted its contract liabilities to CNY 7,055,936.56, reflecting changes in accounting standards[41]